Abstract:BackgroundAutoimmune Encephalitis (AE) is a rare but debilitating neurological disease where the body develops antibodies against neuronal cell surface/synaptic proteins. Rituximab is an anti‐CD20 chimeric monoclonal antibody which shows promise in AE treatment observational studies. To our knowledge, there has been no previous meta‐analysis providing robust evidence on the effectiveness and safety of rituximab as second‐line therapy for the treatment for AE. MethodsThis study was conducted according to the PRISMA (Preferred Reporting Items for Systemic review and Meta‐Analysis) statement. Investigators independently searched PubMed, Web of Science, Google Scholar, WANFANG, CNKI and J‐STAGE for studies. Meta‐analysis via representative forest plots was conducted for good functional outcome (mRS ≤ 2), proportion of relapse and mRS score change pre and post‐treatment. ResultsGood functional outcome at last follow‐up following rituximab therapy occurred in 72.2% of patients (95% CI: 66.3%–77.4%). Mean mRS score decreased by 2.67 (95% CI: 2.04–3.3; p <0.001). Relapses following the rituximab therapy occurred in only 14.2% of patients (95% CI: 9.5%–20.8%). Infusion related reactions, pneumonia and severe sepsis were seen in 29 (15.7%), 11 (6.0%) and 2 patients (1.1%) respectively. The efficacy and side effect profile of rituximab is comparable to outcomes seen in rituximab use in other autoimmune and inflammatory CNS disease. ConclusionOur meta‐analysis showed that rituximab is an effective second line agent for AE with an acceptable toxicity profile.

Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis